Chris Wilson PhD FRSC has more than 10 years senior leadership experience in the medical device field and 15 years leading R&D in life science, pharma and medical devices. Chris has extensive experience in the development, regulatory approval and commercialization of medical devices. Chris’ passion lies at the interface between advanced materials, electronics and the human body.

Chris started his career in academic research at the University of Pennsylvania working on artificial and proto cell mimics during his academic career he has promoted 4 PhD students and holds the title of Fellow of both Royal Society of Chemistry and the Royal Society of Medicine demonstrating his passion to combine the construction of molecular architectures and advanced materials with innovation in healthcare.

Chris has spent the majority of his career in the commercialization of medical devices firstly at Smith and Nephew Plc at global operations for wound management developing advanced wound care solutions and later as CEO and founder of NovioSense BV the first truly non-invasive glucose sensor with clinically acceptable accuracy for diabetics. Chris is a recognized expert in wearable health sensors and has developed a platform for NFC powered medical sensor systems leading the development of medical devices and proprietary semiconductors. Currently Chris remains managing director of NovioSense BV as well as running his own boutique advisory firm often partnering with Whale Bay to help investors and company founders in realizing the full potential of their value proposition.

Charlie has over 20 years of management consulting, business development, and investing experience in more than 40 countries. He is SVP, Strategy, at Cooley LLP, a global law firm that has extensive experience working with life science and tech companies and venture funds. Charlie’s experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies and has been a judge for business plan competitions in the US and in Europe.

He co-founded the Hub Angel Investment Group which is now on its 5th fund. He works with entrepreneurs and innovators in the US and Europe, and especially with German companies. Charlie has built a global network of entrepreneurs, investors, innovators, and others.
>He is a frequent speaker, judge, and panelist related to venture capital and entrepreneurship. In addition, he is VP and a board member of the German-American Business Council, Boston, advisory board member of the Charite Entrepreneurship Summit, board member of Hub Angels and an advisory member of the Technology Capital Network.

He has an MBA, MPH, and BA, Economics – honors.

Dr. Gullans has broad experience across the life sciences industry including being a board director at Gemphire since 2016. Previously Dr. Gullans was Managing Director at Excel Venture Management, a Boston-based life sciences venture capital firm which he co-founded in 2008. At Excel, he spearheaded many successful investments in a variety of therapeutics and diagnostics companies, including Cleveland HeartLab. Prior to Excel, Dr. Gullans was co-founder and CEO of RxGen, Inc. and Chief Scientific Officer at U.S. Genomics.

Currently, Dr. Gullans is a director and co-founder of Orionis Biosciences LLC, a biotech therapeutics company and a director of N-of-One Inc., an oncology diagnostics entity. He advises on innovation at the Cleveland Clinic and Partners HealthCare.

For nearly 20 years, Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital where he published more 130 research papers in many fields. Dr. Gullans is passionate about innovation and co-authored two books with Juan Enriquez, including “Evolving Ourselves,” a book that provides a sweeping tour of how humans are changing the course of evolution. Dr. Gullans has spoken globally including at TEDMED and TEDx. He received his Ph.D. from Duke University, post-doctoral training at Yale University, and his B.S. from Union College. He is an elected Fellow of the American Heart Association as well as the American Association for the Advancement of Science.

Cees is co-founder and executive director of the HUB. Together with Jasper he is overall responsible for the HUB program and the Dutch operations. Cees has a background in corporate law with more than a decade of experience in the fields of life sciences, innovation, IP, strategy and execution. Cees is also partner of Whale Bay & Co. Before founding HUB and Whale Bay & Co, Cees worked at Deloitte, and Simmons & Simmons serving a variety of clients. ​

Senior Executive with international experience in Biotechnology and Pharma. Management appointments in Large and Mid-Cap US/EU Biopharma companies. Proven track record with product approvals, financing, M&A and IPO. Part of the management Team that Roadshowed ZymoGenetics inc (Nasdaq: ZGEN) through Private Placement, IPO and follow-on offerings. Incorporated ProFibrix Inc in 2008, and as CEO in 2013 led ProFibrix through M&A with The Medicines Company after successful Phase 3 completion and product approvals in EU and US. Board appointments in private and public companies.

Present:
Independent Board Director of Polyganics BV
Chairman of the Board G-therapeutics
Chairman of the Board Biom’Up Sas
Chairman of the Board Blaze Therapeutics Inc.

Previous:
Snr VP The Medicines Company
CEO Profibrix BV
Board Director Avigen Inc
Exec VP Mediquest Therapeutics Inc
Snr VP ZymoGenetics Inc
Director Novo Nordisk A/s

Medical Oncology expert with extensive clinical background, strong analytical capabilities, and 20 years in multidisciplinary oncology research & development. Expertise involving biotech drug evaluation, licencing, mergers and acquisitions, mid to late stages clinical development ( NDAs/MAAs; Taxotere, Eloxatin, Xtandi, Onyvide, Oncaspar & Iclusig) and early phases of Immune-Oncology.

Demonstrated effective leadership in various aspects of business development, strategic clinical development planning, trial design, execution, led cross functions & vendor management.
Track record of leadership bringing innovative approaches for improving efficiency, quality, accountability, team building and external partnership collaboration.

Babak Movassaghi, PhD, MBA is an entrepreneur and leader working to harness technology to help patients around the world access better healthcare. As Founder and President of InfiniteMD, he draws upon his success in international business development, operational transformation, team building, product innovation, and investments to form strategic business alliances, driving InfiniteMD’s innovation and growth.

Babak served as VP of Innovation & New Ventures and General Manager of the Boston Innovation Center for Flex, where he operated a multi-million dollars annual P&L and generated a manufacturing pull-through of over $120M within the first year. At Flex, Babak established productive partnerships with major corporations and organizations including Amazon Robotics, Amgen, Booz Allen Hamilton, Liberty Mutual, GE Ventures, and the U.S. Department of Defense, and oversaw Flex’s corporate venture arm, evaluating and funding mid-stage technology and IP-driven startups.

Babak is also an award-winning technological innovator. During his time at Philips Healthcare Babak co-invented and prototyped 3 methods for the diagnosis and treatment of coronary arterial disease that are currently products on the market generating $170+M in sales. He has served as the COO of 2nd.MD, one of the leading medical second opinion tele-health companies in the US, where he was responsible for the clinical and IT operations. Babak is known for his ability to combine advances in health technology with creative business strategies. He is the inventor/co-inventor of over 40 patents, 3 published books, and 40+ peer-reviewed journal articles, and has addressed international and domestic conferences as a keynote speaker.

Babak holds a PhD in Biomedical Engineering from Utrecht University, a Masters in theoretical Physics from the University of Dusseldorf, and an MBA from Massachusetts Institute of Technology.

Rajiv (Raj) Gupta, MD, PhD is a neuroradiologist and ER radiologist in Boston, MA, an Associate Professor of radiology at Harvard Medical School, and a lecturer in Mechanical Engineering at MIT. He is interested in both research and clinical practice of radiology, currently devoting approximately 50% of his time to each of these activities.

His research is currently focused on three main topics: 1) development and clinical applications of novel X-ray imaging modalities including phase contrast imaging, ultra-high resolution computed tomography (CT), and dual-energy CT; 2) development of low-cost devices for imaging and image-guided interventions; and 3) study of traumatic brain injury (TBI) using advanced, quantitative MRI techniques.

Rory Carrillo has extensive product development, quality, and regulatory (ISO13485, FDA, CE Mark) experience, and has developed and successfully led the regulatory clearance for many Class II and Class III products, both hardware and software. He has experience with developing and receiving clearance for digital health, wearable, and AI-based products including algorithms used for detection and diagnosis.

He works with early-stage startups to go from concept to commercialization, providing mentorship and consulting services in all areas for regulatory clearance including due diligence and strategic planning.

I am a savvy strategist & business developer with 20 years of experience in the Life Sciences. Currently, I am the CBO of TRACER Europe and North America, and the CEO of AxelaRx Biosciences Inc.

I am passionate about employing my industry knowledge, global network and broad experience to support Life Sciences companies and their management teams at critical and transformational points in their struggle for survival and growth.

My mission is to maximize the value of promising Life Sciences companies.

Renata is a highly successful Global Pharmaceutical Project and Functional Leader with 30+ years extensive experience in the scientific and clinical development, regulatory approval and commercialisation of new medicines. Renata started her career in academic research at St Thomas’s Hospital, London working on cardiovascular research and heart transplantation.
She joined the Drug Development Dept. at Hoffman La Roche gaining > 30 years extensive experience in the scientific and clinical development, regulatory approval and commercialisation of new medicines.

Renata spent the majority of her pharmaceutical career in early clinical development, initially as a Clinical Pharmacologist in the CVS, Infectious Diseases, and CNS therapeutic areas, then was promoted to lead the Clinical Pharmacology group, responsible for delivery of all the Roche Clinical Pharmacology Programmes.
As a Project Leader, she then led project teams at all stages of development from the early discovery phase to life-cycle management for Roche’s key projects across all therapeutic areas including Tamiflu the influenza drug, Avastin and Obinutuzumab Oncology molecules.
Renata’s most recent role in Roche was global Head of Early Development.
She joined Cancer Research UK in early 2015, as Head of the study, project and portfolio management group responsible for the in-licensing and development of a portfolio of ~ 25 oncology products.


Renata holds a number of Non-Executive Directorships, is a member of Scientific Advisory Boards for several Biotech companies, is a member of the Policy committee of the Faculty of Pharmaceutical Medicine and is a trustee of the PTEN Research Foundation.
Renata is also a lecturer in drug development, phase 1 clinical development and a faculty member lecturing on strategy and leadership on an MBA programme. She has also mentored a wide range of individuals from the start of their careers, helping them develop through junior into senior leadership roles.